Canaccord Adams initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy rating and $57 target.

Canaccord analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE